Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.63 |
| ▸ | HPGD | P15428 | 3/20 | 0.63 |
| ▸ | PDE6D | O43924 | 1/20 | 0.62 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.62 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 4/20 | 0.60 |
| ▸ | PRKACA | P17612 | 1/20 | 0.59 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.59 |
| ▸ | GSK3B | P49841 | 1/20 | 0.59 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13784140 | 0.90 | HSD17B10 (0.58) | ALDH1A1SMN1; SMN2HSD17B10LMNATSHR | |
| SCHEMBL31267426 | 0.88 | KDM4E (0.72) | ALDH1A1SMN1; SMN2HSD17B10LMNATSHR | |
| SCHEMBL22819342 | 0.86 | KDM4E (0.73) | ALDH1A1SMN1; SMN2HSD17B10LMNATSHR | |
| SCHEMBL13299519 | 0.85 | NLRP3 (0.72) | ALDH1A1SMN1; SMN2HSD17B10LMNATSHR | |
| SCHEMBL12145817 | 0.83 | KDM4E (0.67) | ALDH1A1SMN1; SMN2HSD17B10LMNATSHR | |
| SCHEMBL13451619 | 0.83 | KDM4E (0.62) | ALDH1A1SMN1; SMN2HSD17B10LMNATSHR | |
| SCHEMBL31267379 | 0.82 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2HSD17B10LMNAKDM4E | |
| SCHEMBL13127436 | 0.81 | LMNA (0.73) | ALDH1A1SMN1; SMN2LMNATSHRKDM4E | |
| SCHEMBL5009162 | 0.81 | KDM4E (0.77) | ALDH1A1SMN1; SMN2HSD17B10LMNATSHR | |
| SCHEMBL15314761 | 0.80 | KDM4E (0.58) | ALDH1A1HSD17B10LMNATSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501786-B2 | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8367223-B2 | Heteroleptic phosphorescent emitters | UNIVERSAL DISPLAY CORPORATION (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367223-B2 | Heteroleptic phosphorescent emitters | UNIVERSAL DISPLAY CORPORATION (US) | 2013-02-05 | — | — | US | disclosed |
| US-20110028461-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC | 2011-02-03 | — | — | US | disclosed |
| US-20100144591-A1 | BENZIMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-06-10 | — | — | US | disclosed |
| US-20100141127-A1 | PHOSPHORESCENT EMITTERS | UNIVERSAL DISPLAY CORPORATION (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100141127-A1 | PHOSPHORESCENT EMITTERS | UNIVERSAL DISPLAY CORPORATION (US) | 2010-06-10 | — | — | US | disclosed |
| WO-2010056669-A1 | PHOSPHORESCENT EMITTERS | UNIVERSAL DISPLAY CORPORATION (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | SCHERING CORPORATION | 2007-06-21 | — | — | US | disclosed |
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | SCHERING CORPORATION | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | CNR2, GPR119, GLP1R | ALDH1A1 3184/4885SMN1; SMN2 4298/4885HSD17B10 525/4885 |
| US-20100141127-A1 | PHOSPHORESCENT EMITTERS | PAICS, TYMP, NUDT1 | ALDH1A1 695/4885SMN1; SMN2 3461/4885HSD17B10 4746/4885 |
| US-20110028461-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | ALDH1A1 352/4885SMN1; SMN2 3396/4885HSD17B10 1355/4885 |
| US-20100144591-A1 | BENZIMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GK, GCK | ALDH1A1 612/4885SMN1; SMN2 1534/4885HSD17B10 936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.